Bright Minds Biosciences (DRUG) Operating Leases (2022 - 2025)

Bright Minds Biosciences (DRUG) has 4 years of Operating Leases data on file, last reported at $12006.9 in Q4 2025.

• Quarterly Operating Leases fell 84.76% year-over-year to $12006.9 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12006.9 (down 84.76% YoY) and the FY2025 annual result came in at $29973.0, up 3.31% from the prior year.
• Operating Leases declined to $12006.9 in Q4 2025, from $29973.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $107276.2 in Q3 2022 to a low of $10434.2 in Q2 2023.
• A 4-year average of $45047.0 and a median of $40197.5 in 2022 frame the typical range for Operating Leases.
• The widest YoY moves for Operating Leases: up 3.31% in 2025, down 84.76% in 2025.
• Tracing DRUG's Operating Leases over 4 years: stood at $40197.5 in 2022, then surged by 36.48% to $54862.4 in 2023, then surged by 43.62% to $78792.1 in 2024, then tumbled by 84.76% to $12006.9 in 2025.
• The last three Operating Leases figures came in at $12006.9 (Q4 2025), $29973.0 (Q3 2025), and $45353.9 (Q2 2025), per Business Quant data.